Pipeline
Developing
best-in-class skin treatments.
Our unique dermatology drug development platform and expertise fuel our commitment to meaningful innovation that meets the urgent needs of patients.
Broad and deep pipeline.
| Preclinical | Phase 1 | Phase 2 | Phase 3 | NDA Submitted to FDA | ||
|---|---|---|---|---|---|---|
Topical Roflumilast CreamPDE4i* |
||||||
Topical Roflumilast CreamPDE4i* |
Atopic Dermatitis |
|||||
Topical Roflumilast FoamPDE4i* |
||||||
Topical Roflumilast FoamPDE4i* |
Seborrheic Dermatitis |
|||||
Scalp and Body Psoriasis |
||||||
ARQ-252JAK1i** |
||||||
ARQ-252JAK1i** |
Chronic Hand Eczema |
|||||
Vitiligo |
||||||
ARQ-255JAK1i** |
||||||
ARQ-255JAK1i** |
Alopecia Areata |
|||||
*Phosphodiesterase-4 inhibitor (PDE4i)
**Janus kinase 1 inhibitor (JAK1i)
Arcutis’ pipeline will change as molecules move through the drug development process. Safety and efficacy of these investigational agents has not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.
Tackling the most persistent challenges in treating immune-mediated dermatological diseases and conditions.
Arcutis focuses on biologically validated targets that offer the opportunity for development and commercialization on a shorter timeline to regulatory approval, at a lower overall cost of development.
Our robust pipeline includes best-in-class molecules developed from key targets of inflammatory dermatological conditions, such as PDE4 and JAK1.
Featuring multiple clinical programs for a range of immune-mediated conditions, our pipeline includes formulations that have achieved significant results in our clinical trials.
Combined with our unique formulation expertise, we have developed proprietary topical formulations optimized to deliver medication into the skin.
Learn more about how our pipeline is bringing meaningful innovation to life.
Meaningful innovation
is here.
See what our first FDA approval means for the treatment of immune-mediated skin conditions.
Learn More